Concepedia

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII

Mark Rosenthal, Richard Curry, David A. Reardon, Erik Rasmussen, Vijay Upreti, Michael A. Damore, Haby Henary, John S. Hill, Timothy F. Cloughesy

Cancer Chemotherapy and Pharmacology · 2019 · 54 citations · 13 references

DOI

Concepts

References

13

Response criteria for phase II studies of supratentorial malignant glioma.

David R. Macdonald, T L Cascino, S. Clifford Schold et al. · Journal of Clinical Oncology · 1990 · 2.4K citations

, , +17

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Gail D. Lewis Phillips, Guangmin Li, Debra L. Dugger et al. · Cancer Research · 2008 · 1.7K citations

, , +17

Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors

Ingo K. Mellinghoff, Maria Y. Wang, Igor Vivanco et al. · New England Journal of Medicine · 2005 · 1.4K citations · Full text

, , +16

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

Michael Weller, Nicholas Butowski, David Tran et al. · The Lancet Oncology · 2017 · 1.1K citations

, , +13

Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

Rameen Beroukhim, Gad Getz, Leia Nghiemphu et al. · Proceedings of the National Academy of Sciences · 2007 · 1.1K citations · Full text

, , +17